- 1、本文档共65页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
早期强化胰岛素治疗在2型糖尿病中的作用
强 化 降 糖 血糖良好控制 低血糖 依从性不佳 体重增加 疗效的 争议 比我们现在做到的更早开始胰岛素治疗和胰岛素强化治疗,生活质量不会因胰岛素的使用而受到影响。 Analyses adjusting for insulin sensitivity showed that β-cell function was compromised in IGT, DM2h, DMf, and DM, relative to NGT, by 13, 12, 59, and 62% (HOMA-B) and by as much as 40, 60, 80, and 75%, using AIR. * * Results Between-group differences in glycated hemoglobin levels were lost after the first year. In the sulfonylurea–insulin group, relative reductions in risk persisted at 10 years for any diabetes-related end point (9%, P=0.04) and microvascular disease (24%, P=0.001), and risk reductions for myocardial infarction (15%, P=0.01) and death from any cause (13%, P=0.007) emerged over time, as more events occurred. In the metformin group, significant risk reductions persisted for any diabetes-related end point (21%, P=0.01), myocardial infarction (33%, P=0.005), and death from any cause (27%, P=0.002). Conclusions Despite an early loss of glycemic differences, a continued reduction in microvascular risk and emergent risk reductions for myocardial infarction and death from any cause were observed during 10 years of post-trial follow-up. A continued benefit after metformin therapy was evident among overweight patients. * * RESULTS— After 1 year the glucagon-stimulated C-peptide response was increased in the insulin-treated group by 0.140.08 nmol/l, whereas it was decreased by 0.120.08 nmol/l in the glibenclamide group, P 0.02 for difference between groups. After 2 years, fasting insulin levels were higher after treatment withdrawal in the insulin-treated versus the glibenclamidetreated group (P 0.02). HbA1c levels decreased significantly during the first year in both groups; however, at the end of the second year, HbA1c had deteriorated in the glibenclamide group (P 0.01), but not in the insulin-treated group. The difference in evolution of HbA1c during the second year was significant between groups, P 0.02. A questionnaire indicated no difference in well-being
您可能关注的文档
- 各大学法学历年考研真题.doc
- 考研国际经济法新论笔记精编.doc
- 各校中文系语言学考研题大全.doc
- 中外教育管理史复习资料.doc
- 教育学考研外国教育史复习资料.doc
- 刑事诉讼法练习题汇编.doc
- 中医临床医师温病学三基训练.doc
- 社会学研究方法考研复习资料.doc
- 思想政治教育考研复习资料.doc
- 中国古代文学史考研笔记及真题.doc
- 分析let s单元56ago2卷纸zheng unit56.pdf
- 塑胶材料其它分类原料pa9t 12.pdf
- md16x16数字媒体切换器设备.pdf
- 者参考项目发起人学科类型单位序列承包商修订页代码顺序典型.pdf
- 届世界天然气大会阿姆斯特丹2006add10288.pdf
- 期测试记录表每周weekly g1g6 journeys tests level 6 lesson26.pdf
- modernize-whitepaper现代化您应用程序白皮书.pdf
- anybackup产品典型案例分析.pdf
- 约克金融工程课程tfeslide32.pdf
- 广州市妇女儿童医疗中心历份教学药历01tjy.pdf
文档评论(0)